{
    "eid": "2-s2.0-84929453923",
    "title": "Cost-utility analysis of an adjunctive recombinant activated factor VIIa for on-demand treatment of bleeding episodes in dengue haemorrhagic fever",
    "cover-date": "2015-06-06",
    "subject-areas": [
        {
            "$": "Hematology",
            "@code": "2720"
        }
    ],
    "keywords": [
        "cost-utility analysis",
        "decision tree model",
        "dengue haemorrhagic fever",
        "recombinant activated factor VIIa"
    ],
    "authors": [
        "Cho Naing"
    ],
    "citedby-count": 2,
    "ref-count": 28,
    "ref-list": [
        "Global Strategy for Dengue Prevention and Control 2012-2020",
        "Classifying dengue: A review of the difficulties in using the WHO case classification for dengue haemorrhagic fever",
        "F1000 Med Rep",
        "Revised and Expanded Edition",
        "Coagulation abnormalities in dengue hemorrhagic fever: Serial investigations in 167 Vietnamese children with dengue shock syndrome",
        "Preventive transfusion in dengue shock syndrome - Is it necessary?",
        "Lack of efficacy of prophylactic platelet transfusion for severe thrombocytopenia in adults with acute uncomplicated dengue infection",
        "The use of recombinant activated factor VII for controlling life-threatening bleeding in Dengue Shock Syndrome",
        "Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: A randomized, double-blind, placebo-controlled study",
        "Use of recombinant activated factor vii in patients without hemophilia: A meta-analysis of randomized control trials",
        "Safety of recombinant activated factor VII in randomized clinical trials",
        "Bleeding in patients using new anticoagulants or antiplatelet agents: Risk factors and management",
        "Thromboembolic adverse events after use of recombinant human coagulation factor VIIa",
        "BMC Neurol",
        "Quality of life of dengue patients",
        "Use of multiple data sources to estimate the economic cost of dengue illness in Malaysia",
        "Calculating QALYs, comparing QALY and DALY calculations",
        "The Global Burden of Disease: 2004 Update",
        "Economic impact of dengue fever/dengue hemorrhagic fever in Thailand at the family and population levels",
        "An empiric estimate of the value of life: Updating the renal dialysis cost-effectiveness standard",
        "Recommendations of the panel on cost-effectiveness in health and medicine",
        "Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature",
        "Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: Analysis from the Hemophilia and Thrombosis Research Society Registry",
        "Inhibition of thrombin generation by the zymogen factor VII: Implications for the treatment of hemophilia A by factor VIIa",
        "The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis",
        "A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors",
        "Recombinant Activated Factor VII in Cardiac Surgery: A Systematic Review",
        "Recombinant-activated factor VII for control and prevention of hemorrhage in nonhemophilic pediatric patients"
    ],
    "affiliation": [
        {
            "affiliation-city": "Kuala Lumpur",
            "affilname": "International Medical University",
            "affiliation-country": "Malaysia"
        },
        {
            "affiliation-city": "Bangkok",
            "affilname": "Chulalongkorn University",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Chulalongkorn University",
        "National Science and Technology Development Agency"
    ]
}